Tags

Type your tag names separated by a space and hit enter

[Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
Nervenarzt. 2000 Feb; 71(2):78-83.N

Abstract

Registration of the inhibitor of the catechol-O-methyltransfersase (COMT) tolcapone has been stopped due to the possible relationship of tolcapone treatment to three cases of fatal hepatitis. As a result, strong uncertainty has emerged among neurologists about the principle of COMT inhibition itself. We review data, especially on the remaining COMT inhibitor, entacapone, with regard to pre-clinical and clinical efficacy and safety.

Authors+Show Affiliations

Neurologische Klinik und Poliklinik, Universitätsklinikum Charité, Humboldt-Universität Berlin. guy.arnold@charite.deNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

ger

PubMed ID

10703007

Citation

Arnold, G, and A Kupsch. "[Inhibition of catechol-O-methyltransferase. Optimizing Dopaminergic Therapy in Idiopathic Parkinson Syndrome With Entacapone]." Der Nervenarzt, vol. 71, no. 2, 2000, pp. 78-83.
Arnold G, Kupsch A. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Nervenarzt. 2000;71(2):78-83.
Arnold, G., & Kupsch, A. (2000). [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Der Nervenarzt, 71(2), 78-83.
Arnold G, Kupsch A. [Inhibition of catechol-O-methyltransferase. Optimizing Dopaminergic Therapy in Idiopathic Parkinson Syndrome With Entacapone]. Nervenarzt. 2000;71(2):78-83. PubMed PMID: 10703007.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. AU - Arnold,G, AU - Kupsch,A, PY - 2000/3/7/pubmed PY - 2000/4/1/medline PY - 2000/3/7/entrez SP - 78 EP - 83 JF - Der Nervenarzt JO - Nervenarzt VL - 71 IS - 2 N2 - Registration of the inhibitor of the catechol-O-methyltransfersase (COMT) tolcapone has been stopped due to the possible relationship of tolcapone treatment to three cases of fatal hepatitis. As a result, strong uncertainty has emerged among neurologists about the principle of COMT inhibition itself. We review data, especially on the remaining COMT inhibitor, entacapone, with regard to pre-clinical and clinical efficacy and safety. SN - 0028-2804 UR - https://www.unboundmedicine.com/medline/citation/10703007/[Inhibition_of_catechol_O_methyltransferase__Optimizing_dopaminergic_therapy_in_idiopathic_Parkinson_syndrome_with_entacapone]_ L2 - https://dx.doi.org/10.1007/s001150050011 DB - PRIME DP - Unbound Medicine ER -